Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD refers Hollywood Health and Beauty to FTC

This article was originally published in The Tan Sheet

Executive Summary

The Council of Better Business Bureaus' National Advertising Division refers advertising for the weight-loss supplement Trimball-EXP200 to the Federal Trade Commission and FDA after marketer Hollywood Health and Beauty failed to respond to the industry self-regulation group's request for substantiation. NAD asked Hollywood Health and Beauty to support claims that Trimball-EXP200 "triggers automatic weight loss" and allows users to eat as much as they want and still lose weight. Testimonials that users lost "exactly 33 pounds without any effort" and "48 pounds in 7 weeks" also raised red flags. Under FTC's recently tightened guidelines for weight-loss testimonials, it is no longer sufficient to include a disclaimer that weight-loss results are not typical. Firms should disclose typical results, FTC says (1"The Tan Sheet" Oct. 12, 2009)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel